此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

2021年1月29日 更新者:University Hospital Tuebingen

An Open Label Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Nivolumab in Patients With Four and More Symptomatic Brain Metastases of Melanoma

Up to 50% of patients with unresectable metastatic melanoma will develop brain metastases during their lifetime. A possible treatment options for patients with brain metastases are surgery and radiotherapy but usually for lesions in the range of < 3 brain metastases. This study was performed to evaluate the addition of immune checkpoint inhibitors in patients with stage IV melanoma with > 3 symptomatic brain metastases, who are not eligible for surgery or radiosurgery.

研究概览

详细说明

Brain metastases are a frequent problem in patients with melanoma. Up to 50% of patients with unresectable metastatic melanoma will develop brain metastases during their lifetime with a median overall survival of 4 months. Surgical removal or stereotactic radiosurgery of brain metastases can improve overall survival in patients with a limited number of lesions, usually in the range of one to three brain metastases depending on neuroanatomical localization. This benefit is no longer present when considering patients with > 3 brain metastases. As cytotoxic chemotherapy and multiple chemotherapeutic agents show only limited activity in > 3 brain metastases patients, immune checkpoint inhibitors such as ipilimumab and nivolumab offer new opportunities to improve disease outcomes for these patients.

This open label phase II study evaluates safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with stage IV melanoma with four or more symptomatic brain metastases, who are not eligible for surgery or radiosurgery.

研究类型

介入性

注册 (实际的)

6

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Buxtehude、德国
        • Elbe Kliniken Stade - Buxtehude GmbH
      • Dresden、德国
        • Universitätsklinik Carl Gustav Carus Dresden
      • Erfurt、德国
        • Helios Klinikum Erfurt
      • Essen、德国
        • Universitätsklinikum Essen
      • Heidelberg、德国
        • Universitatsklinikum Heidelberg
      • Ludwigshafen、德国
        • Gesellschaft für Klinische Forschung Ludwigshafen mbH
      • Mannheim、德国
        • Universitätsklinikum Mannheim
      • München、德国
        • Klinikum rechts der Isar
      • Quedlinburg、德国
        • Harzklinikum Dorothea Christiane Erxleben GmbH
      • Regensburg、德国
        • Universitätsklinikum Regensburg
      • Tübingen、德国
        • Universitatsklinikum Tubingen

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Signed informed consent (ICF) prior to any screening procedures being performed
  • Ability to comply with protocol requirements
  • Metastatic histologically confirmed melanoma that is unresectable
  • Presence of > 3 active brain metastases confirmed/evaluated by MRI
  • Measurable disease by MRI per iRANO and RECIST 1.1 criteria
  • The time between the baseline MRI and the date of registration should not exceed 28 days. Steroid treatment is permissible before brain MRI evaluation but the dose should have been stable for at least 7 days and should be carefully documented
  • Patient must agree to the cerebro-spinal fluid (CSF) collections according to the study protocol
  • Patients naïve for systemic treatment are eligible
  • Patients pretreated with systemic immunotherapy, targeted therapy or chemotherapy are eligible (exception: previous treatment with the combination of CTLA-4 and PD-1 antibodies)
  • Patients must have recovered completely from any treatment-related acute toxicity associated with prior therapy
  • At least two weeks must have passed since the last systemic anti-cancer treatment
  • Patients with prior local therapy of brain metastases are eligible
  • Patients may have received irradiation therapies: A) None; B) Whole brain irradiation only, C) Stereotactic irradiation of single or few metastases, D) Combined B+C)
  • Screening laboratory values within 14 days prior to registration must meet the criteria: WBC ≥ 2,000/μL, Neutrophils ≥ 1,500/μL, Platelets ≥ 100 x103/μL, Hemoglobin > 9.0 g/dL, Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min, AST/ALT ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN (except patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL), INR ≤ 1.5
  • ECOG Performance Status 0, 1 or 2
  • Expected life expectancy of ≥ 3 months
  • Males and females ≥ 18 years old
  • Negative serum pregnancy test within 24 hours prior to the start of study drug for women of childbearing potential (WOCBP)
  • Women must not be breastfeeding
  • WOCBP must agree to follow instructions for method(s) of contraception, as indicated in the ICF, throughout the study and for 23 weeks after the last dose of investigational drug
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception, as indicated in the ICF, throughout the study and for a period of 31 weeks after the last dose of investigational drug. In addition, male patients must be willing to refrain from sperm donation during this time
  • Azoospermic males are exempt from contraceptive requirements. WOCBP who are permanently not heterosexually active are also exempt from contraceptive requirements, but must still undergo pregnancy testing as previously described.
  • Patients must agree to use at least two methods of contraception, with at least one highly effective method as listed in the ICF

Exclusion Criteria:

  • Diagnosed ocular melanoma
  • Previous systemic therapy with the combination of CTLA-4 and PD-1 antibodies
  • Use of any investigational or non-registered product within the 30 days before registration in the study
  • Prior active malignancy within the previous 3 years except locally curable cancers that have been apparently cured, such as: basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix, or breast
  • History of organ transplantation
  • Active infection requiring systemic therapy
  • Active, known or suspected autoimmune disease (exceptions: patients with controlled Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders not requiring systemic treatment).
  • Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
  • Any serious or uncontrolled medical disorders thatmay increase the risk associated with study participation or study drug administration, impair the ability of the patient to receive protocol therapy, or interfere with the interpretation of study results in the opinion of the investigator
  • Known substance abuse or psychiatric disorders that would preclude cooperation with tany requirements of the trial
  • Legal incapacity or limited legal capacity
  • Administration of live, attenuated vaccine within 4 weeks prior to the start of study drug
  • Positive test for HBs Ag or HCV antibody
  • Known history of a positive test for HIV or known AIDS
  • Patients with known allergy or hypersensitivity to any of the study drugs or excipients
  • Patients with results of imaging or radiological examinations indicating increased cerebral pressure which would prevent lumbar puncture

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment Phase
Treatment phase is divided into the "Induction Phase" and "Maintenance Phase". During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only .
In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
其他名称:
  • 欧狄沃
In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
其他名称:
  • 远航

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Intracranial Control Rate after 6 months of treatment
大体时间:6 months
Proportion of patients with complete intracranial responses (CR), partial intracranial responses (PR) or stable intracranial disease (SD) after 6 months of treatment.
6 months

次要结果测量

结果测量
措施说明
大体时间
Overall survival
大体时间:2 years
Number of patients who stay alive after 2 years.
2 years
Progression-free survival
大体时间:2 years
Number of patients without progression after 2 years.
2 years
Stereotactic irradiation or surgery of brain metastases after partial tumor remission
大体时间:2 years
Percentage of patients in whom stereotactic irradiation or surgery of all metastases becomes applicable after partial tumor remission.
2 years
Tolerability according to NCI-CTCAE-Criteria
大体时间:2 years
All adverse events of all grades.
2 years
Best Overall Response Rate with Complete Respone (CR)
大体时间:6 months
Percentage of patients with CR at six months of treatment.
6 months
Best Overall Response Rate with Partial Response (PR)
大体时间:6 months
Percentage of patients with PR at six months of treatment.
6 months
Cognitive function evaluation by standardized diagnostic procedures
大体时间:2 years
Systemic longitudinal neuropsychological evaluation to investigate the influence of therapy on cognitive performance will be performed by standardized diagnostic procedures.
2 years
Quality of life evaluation with RAND 36-Item Health Survey 1.0
大体时间:2 years
Quality of life assessment is evaluated with the RAND 36-Item Health Survey questionnaires which include physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Evaluation will be performed according to the manual.
2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Claus Garbe, Prof.Dr.med.、University Hospital Tuebingen

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年4月10日

初级完成 (实际的)

2021年1月1日

研究完成 (实际的)

2021年1月1日

研究注册日期

首次提交

2018年10月19日

首先提交符合 QC 标准的

2018年10月31日

首次发布 (实际的)

2018年11月2日

研究记录更新

最后更新发布 (实际的)

2021年2月3日

上次提交的符合 QC 标准的更新

2021年1月29日

最后验证

2018年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅